Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SEP-479 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | - |
| Multiple Ascending Dose | EXPERIMENTAL | - |
| Food Effect | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SEP-479 | DRUG | Oral, capsule |
| Placebo | OTHER | Oral, capsule |
Inclusion Criteria: 1. Subjects who are able and willing to provide informed consent 2. Aged 21 to 60 years at the time of consent 3. Have a BMI within the range 18.0 to 32.0 kg/m2 4. In general good health Exclusion Criteria: 1. Any condition, which in the investigator's opinion might jeopardize...
SEP-479 is an investigational small molecule being developed by Septerna, Inc. (NASDAQ: SEPN). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied in a randomized, double-blind, controlled trial to evaluate its safety and tolerability.
SEP-479 targets the parathyroid hormone 1 receptor (PTH1R), which is a G protein-coupled receptor (GPCR). By targeting this receptor, the drug may modulate pathways related to calcium and phosphate metabolism, though its exact therapeutic application has not been specified.
SEP-479 is being developed by Septerna, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol SEPN. The company is conducting a Phase 1 clinical trial of SEP-479 in healthy adult participants.
SEP-479 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate single and multiple doses of the drug.
SEP-479 is being studied in a Phase 1 clinical trial with the identifier NCT07433179. The trial, titled "A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants," is recruiting 150 healthy volunteers in Australia. It is randomized, double-blind, and controlled.
Yes, SEP-479 is being tested in healthy volunteers. The Phase 1 clinical trial NCT07433179 enrolls healthy adult participants aged 21 years and older, of all sexes. The study is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of SEP-479.